featured
First-Line TKI With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of the National Cancer Institute
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated NSCLC
J. Natl. Cancer Inst 2022 Jan 30;[EPub Ahead of Print], XS Wang, YF Bai, V Verma, RL Yu, W Tian, R Ao, Y Deng, JL Xia, XQ Zhu, H Liu, HX Pan, L Yang, YK He, HS Bai, X Luo, Y Guo, MX Zhou, YM Sun, ZC Zhang, SM Li, X Cheng, BX Tan, LF Han, YY Liu, K Zhang, FX Zeng, L Jia, XB Hao, YY Wang, G Feng, K Xie, Y Lu, M ZengFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.